Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Tech companies are a lot like major-league sports stars in that they often post their best results early in their careers.
Athletes' bodies wear out, and they can compete at the highest levels for only so many years.
With high-tech corporations, however, the challenge isn't age or health. It's that there's always a group of young startups with hot innovations breathing down the Old Guard's necks.
There are chances for late-career renaissances, though. And what aging tech leaders need to achieve this is the business equivalent of a performance-enhancing drug – except legal.
I've uncovered four aging Silicon Valley legends that have found just that in a certain fast-moving part of the tech sector.
And one of them has rediscovered its ace-like prowess – and is making investors hefty gains in the process.
Let me tell you about it…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.